Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

• Published in: The lancet oncology Vol. 24; no. 12; pp. 1423 - 1433
• Main Authors: Niemann, Carsten U, Munir, Talha, Moreno, Carol, Owen, Carolyn, Follows, George A, Benjamini, Ohad, Janssens, Ann, Levin, Mark-David, Robak, Tadeusz, Simkovic, Martin, Voloshin, Sergey, Vorobyev, Vladimir, Yagci, Munci, Ysebaert, Loic, Qi, Keqin, Qi, Qianya, Sinet, Pierre, Parisi, Lori, Srinivasan, Srimathi, Schuier, Natasha, Baeten, Kurt, Howes, Angela, Caces, Donne Bennett, Kater, Arnon P
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.12.2023; Elsevier Limited; Elsevier
• Subjects: Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Chemotherapy; Chlorambucil; Chlorambucil - adverse effects; Chlorambucil - therapeutic use; Chronic lymphocytic leukemia; Clinical decision making; Clinical trials; Comorbidity; Creatinine; Female; Follow-Up Studies; Humans; Immunotherapy; Inhibitor drugs; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Life Sciences; Male; Monoclonal antibodies; Mutation; Myelodysplastic syndrome; Patients; Pneumonia; Pneumonia - chemically induced; Survival; Targeted cancer therapy; United States > US

In the GLOW study, fixed-duration ibrutinib–venetoclax showed superior progression-free survival versus chlorambucil–obinutuzumab in patients with previously untreated chronic lymphocytic leukaemia who were older or had comorbidities, or both, at a median follow up of 27·7 months. In this Article, w...